Skip to main content
Premium Trial:

Request an Annual Quote

NIH Awards TriLink $750K Phase II Grant for Structure-Free DNA and RNA Research

NEW YORK, Dec. 15 (GenomeWeb News) - TriLink Bio Technologies has received an STTR Phase II funding from the National Institutes of Health to continue collaborating on the structure-free DNA and RNA program, the company said today.


Company spokesperson Kim Hampson told GenomeWeb News that the award is for $749,405 and will cover the period from January 2006 to Dec. 31, 2007.


TriLink is working with Howard Gamper of Thomas Jefferson University on the project, titled "Reagents for Preparing Structure-Free DNA and RNA." In Phase I, they demonstrated that certain base analogs can enhance accessibility of the pseudo-complementary target sequence to short probes.


The second phase of the project aims to improve the efficiency of hybridization between short oligonucleotide probes and long DNA and RNA targets, the company said.


In this collaboration, TriLink is developing the structure-free DNA and RNA technology while Gamper identifies the best nucleotide candidates which can be enzymatically incorporated into pseudo-complementary nucleic acid targets for improved hybridization performance.


The initial funding was for $99,871 from NIH and covered July to December.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.